Rhythm Biosciences Limited (ASX:RHY)

Australia · Delayed Price · Currency is AUD

0.0970

+0.0050 (5.43%)

Aug 7, 2026, 3:59 PM AEST

-28.15% (1Y)

Market Cap	34.33M +27.2%
Revenue (ttm)	1.65M -48.0%
Net Income	-6.68M
EPS	-0.02
Shares Out	353.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	181,054
Open	0.0920
Previous Close	0.0920
Day's Range	0.0890 - 0.0970
52-Week Range	0.0750 - 0.2800
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Rhythm Biosciences

Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Australia. [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2017

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol RHY

Full Company Profile

Financial Performance

In fiscal year 2025, Rhythm Biosciences's revenue was 3.19 million, an increase of 88.85% compared to the previous year's 1.69 million. Losses were -3.83 million, -44.15% less than in 2024.

Financial Statements